Moderna's Spikevax bivalent Covid-19 vaccine targets both the original Sars-CoV-2 strain and the Omicron BA.1 variant. - Reuters
SINGAPORE (The Straits Times/Asia News Nework): The Health Sciences Authority (HSA) on Wednesday (Sept 140 granted interim authorisation for the use of Moderna's Spikevax bivalent Covid-19 vaccine, which targets both the original Sars-CoV-2 strain and the Omicron BA.1 variant.
The bivalent vaccine has been authorised for use as a booster for people aged 18 and above who have already received their primary series vaccination.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
